Sentences with phrase «lead to cancer therapies»
«Newly discovered cellular pathway may lead to cancer therapies.»
https://www.sciencedaily.com/
Sophisticated genetic circuitry spliced into cells could lead to cancer therapies, tissue generation on demand
Not exact matches
Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).
Not till later did I find out from my OB that my years of diabetes, PCOS and hormone therapy that I received for my endometrial cancer caused hormone imbalances which led to my inability to produce milk.
In October 2016, writing in Mathematical Models and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therapies.
That desire must have led the US surgeon to the first published account of «fever therapy» — treating cancer with pathogenic bacteria.
A group of the nation's leading cancer research scientists and their Cuban counterparts are exploring how to advance cancer therapy, diagnosis, and prevention, including the use of immunotherapy to harness the body's immune systems to attack and eliminate cancer cells.
Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.
Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.
«Ultimately, understanding the interplay between genetic mutations, gut microbes, and inflammation may lead to novel diagnostics and therapies for intestinal cancer.»
Using genomic analysis to study cancer in dogs can help develop new therapies for humans with cancer, according to a proof - of - concept study led by the National Cancer Institute (NCI) and the Translational Genomics Research Institute (cancer in dogs can help develop new therapies for humans with cancer, according to a proof - of - concept study led by the National Cancer Institute (NCI) and the Translational Genomics Research Institute (cancer, according to a proof - of - concept study led by the National Cancer Institute (NCI) and the Translational Genomics Research Institute (Cancer Institute (NCI) and the Translational Genomics Research Institute (TGen).
Professor Ali Tavassoli, who led the study with colleague Dr. Ishna Mistry, explains: «In an effort to better understand the role of HIF - 1 in cancer, and to demonstrate the potential for inhibiting this protein in cancer therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF - 1 inhibiting molecule when placed in a hypoxic environment.
«Programming DNA to deliver cancer drugs: New technology could lead to the development of new cancer therapies.»
They have had several successes in identifying pro-metastasis microRNAs skin cancers and anti-metastatic microRNAs in breast cancer, discoveries that could in the future lead to new, more effective therapies.
While the combination of targeted therapies improves patient outcomes, any remaining cancer cells can lead to drug resistance.
Dr. Xu and his team currently are planning follow - up studies, hopeful that these could lead to a life - extending therapy for pancreatic cancer patients in the not - too - distant future.
The new chimera interferes with HER2 and HER3 signaling and ultimately leads to cancer cell death, as shown in the group's recent publication in Molecular Therapy: Nucleic Acids.
The finding might lead to new therapies for a subset of patients with glioblastoma, the most common and lethal form of brain cancer.
«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.
Identifying the key players behind mutations and cancer may not immediately lead to therapies, he said, but it's important to understand the process.
«Single gene encourages growth of intestinal stem cells, supporting «niche» cells, and cancer: Finding in mice could lead to new therapies for damaged organs, cancer.»
Meanwhile, cancer genome projects have yielded unprecedented insights into the cellular signaling pathways that drive the development and progression of cancer — information that has led to effective therapies tailored for individual patients.
This makes the development of an effective vaccine to protect against infection, as well as antiviral therapy to combat already - existing infections, particularly challenging,» says Dr. Grant Hansman, a virologist who leads the CHS Research Group on Noroviruses at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University.
Cancer stem cells are strongly associated with the growth and recurrence of all cancers and are especially difficult to eradicate with normal treatment, which also leads to tumours developing resistance to other types of therapy.
«RYBP would make cancer cells more sensitive to DNA damage, which would make chemo or radiation therapy more effective,» said Mohammad Ali, a postdoctoral fellow and the lead author of the study.
«Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both.»
«This is why we're diligently working to employ several strategies that we hope will lead us to reaching our ultimate goal of developing the best therapy possible — a therapy that can be given to patients as a first line of defense, greatly reducing the side effects of cancer treatment and leading to a cure.»
A research group at Boston's Massachusetts General Hospital, led by Tayyaba Hasan, has used nanocells and photodynamic therapy (light - activated chemicals) to target pancreatic cancer.
Led by Joke Bradt, PhD, associate professor in Drexel University's College of Nursing and Health Professions, a team looked into studies that examined the impact of music therapy (a personalized music experience offered by trained music therapists) and music medicine (listening to pre-recorded music provided by a doctor or nurse) on psychological and physical outcomes in people with cancer.
In cases of new infection, prompt and targeted therapy is vital, as it can prevent the disease developing into a chronic condition that can lead to inoperable liver cancer.
The finding, published in the current issue of the journal Nature Communications, could lead to new therapies for treating a common sub-type of GBM and possibly other forms of cancer.
In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutacancer patients with B - raf mutations.
Dr. Cooper joined MDACC in 2006 as section chief of cell therapy at the Children's Cancer Hospital, where he cared for children undergoing bone marrow transplantation and led scientific efforts to develop new treatment approaches that pair genetic engineering with immunotherapies.
«Blocking what FAT10 does to coordinate immunity and metabolism could lead to new therapies for metabolic disease, metabolic syndrome, cancer and healthy aging, because when we knock it out the net result is mice live longer.»
These findings may lead to new therapies specifically targeting the altered energy supply chains of cancer cells to get cancer cells to commit suicide.
The findings, which were published online in the journal Cancer Cell, could ultimately lead to new targeted therapies for many other types of cancer carrying similar p53 mutaCancer Cell, could ultimately lead to new targeted therapies for many other types of cancer carrying similar p53 mutacancer carrying similar p53 mutations.
Basic research on cancer mechanisms has led to over 40 targeted cancer therapies currently on the market, which take the form of monoclonal antibodies, small molecule drugs, and immunotherapies.
Additionally, since ribosomal RNA has been shown to have specified controlled of cellular fate, this study provides a theoretical basis for disease therapy and neuroscience research and may lead to future advances in treating degenerative diseases or even brain cancers.
Investigating how organs far from tumors contribute to cancer progression should lead us to ways of manipulating those systemic activities in therapy.
«Unfortunately our paper suggests that tumors don't even need to be heterogeneous genetically, the very fact that they have aneuploidy could lead to very variable outcomes, and that represents a significant challenge for cancer therapy,» Amon says.
It's the first CAR - T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.
«This breakthrough could lead to more effective therapies for women with this very common subtype of breast cancer and be the therapeutic target that the drug companies have been waiting for.»
In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.
Dr. Raquibul Hannan, left, and Dr. Robert Timmerman led a team that successfully used stereotactic body radiation therapy for the first time to treat an often deadly complication of kidney cancer.
«We thought that patients who have CFS breaks might be more sensitive to radiation therapy - induced DNA damage,» said the lead author of the study, Robert G. Bristow, MD, PhD, a Professor within the radiation oncology and medical biophysics departments at the University of Toronto; and a Clinician - Scientist at the Princess Margaret Cancer Centre in Toronto.
Understanding this process can lead to better targeted therapies for pancreatic cancer.
A new study published in the International Journal of Molecular Sciences, describes a new concept of how these two cancers may evolve in a similar way and may eventually lead to more effective therapies for both.
These findings identify specific BRCA1 mutations that are more likely to develop therapy resistance, which may lead to more accurate predictions and personalized treatments for breast and ovarian cancers.
Dr. Timmerman, who holds the Effie Marie Cain Distinguished Chair in Cancer Therapy Research, has championed the use of SABR globally and has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SABR to treat cancer in the lung, liver, spine, and proCancer Therapy Research, has championed the use of SABR globally and has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SABR to treat cancer in the lung, liver, spine, and procancer in the lung, liver, spine, and prostate.
«A better understanding of how inflammation affects stem cells and other components of tissue will revolutionize our understanding of many diseases, including cancer, and likely lead to novel therapies,» Naik says.